Statin Use and Risk of Cognitive Decline in the ADNI Cohort.

Autor:	Kemp EC; Alzheimer's Disease Research Unit, Yale University School of Medicine (ECK, MKE, SR, TAG, EAP, HHB, JWM, CHvD, APM), New Haven, CT; Department of Psychiatry, Yale University School of Medicine (ECK, MKE, SR, TAG, EAP, HHB, JWM, CHvD, APM), New Haven, CT. Electronic address: emilyclairekemp@gmail.com., Ebner MK; Alzheimer's Disease Research Unit, Yale University School of Medicine (ECK, MKE, SR, TAG, EAP, HHB, JWM, CHvD, APM), New Haven, CT; Department of Psychiatry, Yale University School of Medicine (ECK, MKE, SR, TAG, EAP, HHB, JWM, CHvD, APM), New Haven, CT., Ramanan S; Alzheimer's Disease Research Unit, Yale University School of Medicine (ECK, MKE, SR, TAG, EAP, HHB, JWM, CHvD, APM), New Haven, CT; Department of Psychiatry, Yale University School of Medicine (ECK, MKE, SR, TAG, EAP, HHB, JWM, CHvD, APM), New Haven, CT., Godek TA; Alzheimer's Disease Research Unit, Yale University School of Medicine (ECK, MKE, SR, TAG, EAP, HHB, JWM, CHvD, APM), New Haven, CT; Department of Psychiatry, Yale University School of Medicine (ECK, MKE, SR, TAG, EAP, HHB, JWM, CHvD, APM), New Haven, CT., Pugh EA; Alzheimer's Disease Research Unit, Yale University School of Medicine (ECK, MKE, SR, TAG, EAP, HHB, JWM, CHvD, APM), New Haven, CT; Department of Psychiatry, Yale University School of Medicine (ECK, MKE, SR, TAG, EAP, HHB, JWM, CHvD, APM), New Haven, CT., Bartlett HH; Alzheimer's Disease Research Unit, Yale University School of Medicine (ECK, MKE, SR, TAG, EAP, HHB, JWM, CHvD, APM), New Haven, CT; Department of Psychiatry, Yale University School of Medicine (ECK, MKE, SR, TAG, EAP, HHB, JWM, CHvD, APM), New Haven, CT., McDonald JW; Alzheimer's Disease Research Unit, Yale University School of Medicine (ECK, MKE, SR, TAG, EAP, HHB, JWM, CHvD, APM), New Haven, CT; Department of Psychiatry, Yale University School of Medicine (ECK, MKE, SR, TAG, EAP, HHB, JWM, CHvD, APM), New Haven, CT., Mecca MC; Veterans Affairs Connecticut Healthcare System (MCM), West Haven, CT; Department of Internal Medicine, Geriatrics Section, and the Program on Aging, Yale University School of Medicine (MCM), New Haven, CT., van Dyck CH; Alzheimer's Disease Research Unit, Yale University School of Medicine (ECK, MKE, SR, TAG, EAP, HHB, JWM, CHvD, APM), New Haven, CT; Department of Psychiatry, Yale University School of Medicine (ECK, MKE, SR, TAG, EAP, HHB, JWM, CHvD, APM), New Haven, CT; Department of Neuroscience, Yale University School of Medicine (CHvD), New Haven, CT; Department of Neurology, Yale University School of Medicine (CHvD), New Haven, CT., Mecca AP; Alzheimer's Disease Research Unit, Yale University School of Medicine (ECK, MKE, SR, TAG, EAP, HHB, JWM, CHvD, APM), New Haven, CT; Department of Psychiatry, Yale University School of Medicine (ECK, MKE, SR, TAG, EAP, HHB, JWM, CHvD, APM), New Haven, CT.
Jazyk:	angličtina
Zdroj:	The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry [Am J Geriatr Psychiatry] 2020 May; Vol. 28 (5), pp. 507-517. Date of Electronic Publication: 2019 Nov 11.
DOI:	10.1016/j.jagp.2019.11.003
Abstrakt:	Objective: To investigate associations between statin use and cognitive change, as well as diagnostic conversion, in individuals with cognitively normal (CN) status, mild cognitive impairment (MCI), and dementia due to Alzheimer disease (AD-dementia). Methods: A multicenter cohort study with 1629 adults 48 to 91 years old with CN status, early MCI (EMCI), late MCI (LMCI), or AD-dementia at baseline followed prospectively for 24 months. Statin use was assessed at baseline, and cognition was measured over time with a composite memory score, a composite executive function score, and a global cognition score (Alzheimer's Disease Assessment Scale). Conversion to a more impaired diagnostic category was determined by clinician assessment. Repeated measures linear mixed-effects models were used to evaluate associations between statin use and change in cognition over time. Cox proportional hazards models were used to evaluate associations between statin use and time to diagnostic conversion. All models were stratified by baseline diagnostic group. Results: Statin use was not associated with change in cognitive measures for CN, LMCI, or AD-dementia participants. Among EMCI participants, statin use was associated with a significantly slower rate of decline on the memory composite, but no other cognitive measure. Statin use was not associated with time to conversion for any diagnostic group. Conclusions: This study did not support an association between statin use and diagnostic conversion but suggested a possible association between statin use and cognitive change in EMCI. Additional randomized clinical trials of statins may be warranted in the prodromal EMCI stage of AD. (Copyright © 2019 American Association for Geriatric Psychiatry. Published by Elsevier Inc. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu